Rapamycin Inhibits Proliferation and Migration of Hepatoma Cells In Vitro

Journal of Surgical Research

Volumn 159, Issue 2, 2010, Pages 705-713

  Shirouzu, Yasumasa ^a   Ryschich, Eduard ^a   Salnikova, Olga ^a   Kerkadze, Vachtang ^a   Schmidt, Jan ^a   Engelmann, Guido ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Akt; hepatocellular carcinoma; liver transplantation; metastasis; mTOR; rapamycin

Indexed keywords

BROXURIDINE; PROTEIN KINASE B; RAPAMYCIN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL ASSAY; CELL COUNT; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; METASTASIS; MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; SIROLIMUS;

EID: 77949484645     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2008.07.035     Document Type: Article

References (40)

1. Schwartz M., Roayaie S., and Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 4 (2007) 424
2. O'Grady J.G., Polson R.J., Rolles K., et al. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg 207 (1988) 373
3. Olthoff K.M., Millis J.M., Rosove M.H., et al. Is liver transplantation justified for the treatment of hepatic malignancies?. Arch Surg 125 (1990) 1261
4. Ringe B., Pichlmayr R., Wittekind C., et al. Surgical treatment of hepatocellular carcinoma: Experience with liver resection and transplantation in 198 patients. World J Surg 15 (1991) 270
5. Schwartz M., Roayaie S., and Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?. J Hepatol 43 (2005) 584
6. Yokoyama I., Carr B., Saitsu H., et al. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 68 (1991) 2095
7. Duffy J.P., Vardanian A., Benjamin E., et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: A 22-year experience with 467 patients at UCLA. Ann Surg 246 (2007) 502
8. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693
9. Guba M., Graeb C., Jauch K.W., et al. Pro- and anticancer effects of immunosuppressive agents used in organ transplantation. Transplantation 77 (2004) 1777
10. Vivarelli M., Bellusci R., Cucchetti A., et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: Better patient selection or lower immunosuppression?. Transplantation 74 (2002) 1746
11. Hojo M., Morimoto T., Maluccio M., et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397 (1999) 530
12. Maluccio M., Sharma V., Lagman M., et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 76 (2003) 597
13. Manning B.D., and Cantley L.C. AKT/PKB signaling: Navigating downstream. Cell 129 (2007) 1261
14. Hudes G., Carducci M., Tomczak P., et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271
15. Hidalgo M., Buckner J.C., Erlichman C., et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12 (2006) 5755
16. Chan S., Scheulen M.E., Johnston S., et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23 (2005) 5314
17. Toso C., Meeberg G.A., Bigam D.L., et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: Long-term outcomes and side effects. Transplantation 83 (2007) 1162
18. Poon M., Marx S.O., Gallo R., et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 98 (1996) 2277
19. Gomez-Cambronero J. Rapamycin inhibits GM-CSF-induced neutrophil migration. FEBS Lett 550 (2003) 94
20. Rhoads J.M., Niu X., Odle J., et al. Role of mTOR signaling in intestinal cell migration. Am J Physiol Gastrointest Liver Physiol 291 (2006) G510
21. Huber S., Bruns C.J., Schmid G., et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 71 (2007) 771
22. Al-Shami R., Sorensen E.S., Ek-Rylander B., et al. Phosphorylated osteopontin promotes migration of human choriocarcinoma cells via a p70 S6 kinase-dependent pathway. J Cell Biochem 94 (2005) 1218
23. Lang S.A., Gaumann A., Koehl G.E., et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120 (2007) 1803
24. Liu L., Li F., Cardelli J.A., et al. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene 25 (2006) 7029
25. Schumacher G., Oidtmann M., Rueggeberg A., et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 11 (2005) 1420
26. Zhang J.F., Liu J.J., Lu M.Q., et al. Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro. Transpl Immunol 17 (2007) 162
27. Gershtein E.S., Scherbakov A.M., Anurova O.A., et al. Phosphorylated Akt1 in human breast cancer measured by direct sandwich enzyme-linked immunosorbent assay: Correlation with clinicopathological features and tumor VEGF-signaling system component levels. Int J Biol Markers 21 (2006) 12
28. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8 (2005) 179
29. McAlister V.C., Gao Z., Peltekian K., et al. Sirolimus-tacrolimus combination immunosuppression. Lancet 355 (2000) 376
30. Kneteman N.M., Oberholzer J., Al Saghier M., et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 10 (2004) 1301
31. Shah S.A., Potter M.W., Ricciardi R., et al. FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation. J Surg Res 97 (2001) 123
32. Lang S.A. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120 (2007) 1803
33. Buck E., Eyzaguirre A., Brown E., et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5 (2006) 2676
34. Sun S.Y., Rosenberg L.M., Wang X., et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65 (2005) 7052
35. Sarbassov D.D., Ali S.M., Sengupta S., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22 (2006) 159
36. Di Paolo S., Teutonico A., Leogrande D., et al. Chronic inhibition of mammalian target of rapamycin signaling down-regulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes?. J Am Soc Nephrol 17 (2006) 2236
37. Cukierman E., Pankov R., Stevens D.R., et al. Taking cell-matrix adhesions to the third dimension. Science 294 (2001) 1708
38. Edinger A.L., and Thompson C.B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 13 (2002) 2276
39. Sakakibara K., Liu B., Hollenbeck S., et al. Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin. Am J Physiol Heart Circ Physiol 288 (2005) H2861
40. Sarbassov D.D., Ali S.M., Kim D.H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14 (2004) 1296